Research progress on immunosuppressants and new drugs for liver transplantation
10.3969/j.issn.1674-7445.2020.06.003
- VernacularTitle:肝移植临床免疫抑制剂及新药研究进展
- Author:
Quanyu CHEN
1
;
Shifang JIANG
;
Renpei XIA
;
Ling SHUAI
;
Hongyu ZHANG
;
Lianhua BAI
Author Information
1. College of Life Science, Southwest University, Chongqing 400715, China
- Publication Type:Research Article
- Keywords:
Immunosuppressant;
Rejection;
Liver transplantation;
Immune tolerance;
Adverse effect;
Lymphocyte;
Signal transduction;
Monoclonal antibody
- From:
Organ Transplantation
2020;11(6):663-
- CountryChina
- Language:Chinese
-
Abstract:
Immunosuppressants, which are commonly used for liver transplantation, mainly included calcineurin inhibitors, such as ciclosporin (CsA) and tacrolimus (FK506); glucocorticoid drugs, such as prednisone and prednisolone; cytotoxic drugs, such as azathioprine, mycophenolate mofetil and cyclophosphamide; mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus; antibody drugs, such as polyclonal or monoclonal antibodies and interleukin (IL)-2 receptor antibodies, etc. Although many categories of immunosuppressants are available, FK506 is the most commonly adopted in liver transplant recipients. However, FK506 can provoke significant adverse effects in the late stage of liver transplantation, especially severe infection and nephrotoxicity. Consequently, it is an urgent task and research hot spot to develop new immunosuppressants with strong immune tolerance and mild adverse effects in clinical practice. In this article, the research progress on immunosuppressants and the research and development status of new immunosuppressants for liver transplantation were reviewed.
